Eric Coldwell
Stock Analyst at Baird
(3.62)
# 820
Out of 4,754 analysts
181
Total ratings
55.77%
Success rate
3.77%
Average return
Main Sectors:
Stocks Rated by Eric Coldwell
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| AHCO AdaptHealth | Maintains: Outperform | $14 → $16 | $11.38 | +40.60% | 10 | Feb 27, 2025 | |
| OMI Owens & Minor | Maintains: Neutral | $14 → $10 | $9.58 | +4.38% | 16 | Feb 25, 2025 | |
| CRL Charles River Laboratories International | Maintains: Neutral | $177 → $173 | $165.31 | +4.65% | 13 | Feb 20, 2025 | |
| PINC Premier | Maintains: Neutral | $20 → $19 | $18.18 | +4.51% | 7 | Feb 5, 2025 | |
| MEDP Medpace Holdings | Maintains: Neutral | $354 → $362 | $327.32 | +10.60% | 17 | Jan 27, 2025 | |
| IQV IQVIA Holdings | Maintains: Neutral | $212 → $210 | $188.80 | +11.23% | 16 | Jan 21, 2025 | |
| FTRE Fortrea Holdings | Downgrades: Neutral | $28 → $25 | $13.85 | +80.51% | 7 | Dec 6, 2024 | |
| ICLR ICON Public Limited Company | Maintains: Neutral | $249 → $225 | $190.02 | +18.41% | 18 | Nov 20, 2024 | |
| MCK McKesson | Upgrades: Outperform | $531 → $688 | $640.26 | +7.46% | 17 | Nov 7, 2024 | |
| LH Labcorp Holdings | Maintains: Outperform | $282 → $289 | $251.04 | +15.12% | 12 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $157 → $182 | $172.90 | +5.26% | 8 | Oct 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $130 → $137 | $129.48 | +5.81% | 11 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $51 | $10.68 | +377.53% | 16 | Apr 1, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $35 → $45 | $56.74 | -20.69% | 2 | Jun 26, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $62 → $66 | $65.72 | +0.43% | 7 | May 7, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $46 | $1.56 | +2,855.92% | 4 | Nov 10, 2017 |
AdaptHealth
Feb 27, 2025
Maintains: Outperform
Price Target: $14 → $16
Current: $11.38
Upside: +40.60%
Owens & Minor
Feb 25, 2025
Maintains: Neutral
Price Target: $14 → $10
Current: $9.58
Upside: +4.38%
Charles River Laboratories International
Feb 20, 2025
Maintains: Neutral
Price Target: $177 → $173
Current: $165.31
Upside: +4.65%
Premier
Feb 5, 2025
Maintains: Neutral
Price Target: $20 → $19
Current: $18.18
Upside: +4.51%
Medpace Holdings
Jan 27, 2025
Maintains: Neutral
Price Target: $354 → $362
Current: $327.32
Upside: +10.60%
IQVIA Holdings
Jan 21, 2025
Maintains: Neutral
Price Target: $212 → $210
Current: $188.80
Upside: +11.23%
Fortrea Holdings
Dec 6, 2024
Downgrades: Neutral
Price Target: $28 → $25
Current: $13.85
Upside: +80.51%
ICON Public Limited Company
Nov 20, 2024
Maintains: Neutral
Price Target: $249 → $225
Current: $190.02
Upside: +18.41%
McKesson
Nov 7, 2024
Upgrades: Outperform
Price Target: $531 → $688
Current: $640.26
Upside: +7.46%
Labcorp Holdings
Oct 25, 2024
Maintains: Outperform
Price Target: $282 → $289
Current: $251.04
Upside: +15.12%
Oct 23, 2024
Upgrades: Outperform
Price Target: $157 → $182
Current: $172.90
Upside: +5.26%
Aug 15, 2024
Maintains: Outperform
Price Target: $130 → $137
Current: $129.48
Upside: +5.81%
Apr 1, 2022
Downgrades: Neutral
Price Target: $51
Current: $10.68
Upside: +377.53%
Jun 26, 2020
Maintains: Neutral
Price Target: $35 → $45
Current: $56.74
Upside: -20.69%
May 7, 2020
Maintains: Neutral
Price Target: $62 → $66
Current: $65.72
Upside: +0.43%
Nov 10, 2017
Maintains: Outperform
Price Target: $67 → $46
Current: $1.56
Upside: +2,855.92%